DOK6

Summary

DOK6 (docking protein 6, HGNC:28301) is a protein-coding gene on chromosome 18q22.2, encoding Docking protein 6 (Q6PKX4). DOK proteins are enzymatically inert adaptor or scaffolding proteins.

DOK6 is a member of the DOK (see DOK1; MIM 602919) family of intracellular adaptors that play a role in the RET (MIM 164761) signaling cascade (Crowder et al., 2004 [PubMed 15286081]).

Source: NCBI Gene 220164 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 47 total — 1 pathogenic
• MANE Select transcript: NM_152721

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28301
Approved symbol	DOK6
Name	docking protein 6
Location	18q22.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC20785, HsT3226
Ensembl gene	ENSG00000206052
Ensembl biotype	protein_coding
OMIM	611402
Entrez	220164

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000382713, ENST00000577609, ENST00000582172, ENST00000582992, ENST00000584435, ENST00000893242

RefSeq mRNA: 1 — MANE Select: NM_152721 NM_152721

CCDS: CCDS32841

Canonical transcript exons

ENST00000382713 — 8 exons

Exon	Start	End
ENSE00001493062	69841244	69849087
ENSE00001493065	69738965	69739103
ENSE00001493068	69599384	69599498
ENSE00001493069	69564487	69564594
ENSE00001493070	69400888	69401310
ENSE00003503750	69757756	69757873
ENSE00003568234	69677734	69677853
ENSE00003649691	69698404	69698593

Expression profiles

Bgee: expression breadth ubiquitous, 198 present calls, max score 95.81.

FANTOM5 (CAGE): breadth broad, TPM avg 2.2407 / max 58.2956, expressed in 707 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
170704	2.2407	707

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	95.81	gold quality
substantia nigra pars compacta	UBERON:0001965	95.74	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.14	gold quality
Brodmann (1909) area 46	UBERON:0006483	93.06	gold quality
pons	UBERON:0000988	93.02	gold quality
endothelial cell	CL:0000115	91.42	gold quality
middle temporal gyrus	UBERON:0002771	91.35	gold quality
ganglionic eminence	UBERON:0004023	90.48	gold quality
entorhinal cortex	UBERON:0002728	88.87	gold quality
Brodmann (1909) area 23	UBERON:0013554	88.83	gold quality
dorsal root ganglion	UBERON:0000044	88.23	gold quality
ventral tegmental area	UBERON:0002691	87.98	gold quality
superior frontal gyrus	UBERON:0002661	87.88	gold quality
superior vestibular nucleus	UBERON:0007227	87.78	gold quality
cerebellar vermis	UBERON:0004720	86.83	gold quality
temporal lobe	UBERON:0001871	86.80	gold quality
parietal lobe	UBERON:0001872	85.66	gold quality
trigeminal ganglion	UBERON:0001675	85.65	gold quality
prefrontal cortex	UBERON:0000451	85.54	gold quality
medulla oblongata	UBERON:0001896	85.14	gold quality
amygdala	UBERON:0001876	85.13	gold quality
postcentral gyrus	UBERON:0002581	84.82	gold quality
kidney epithelium	UBERON:0004819	84.74	silver quality
anterior cingulate cortex	UBERON:0009835	84.71	gold quality
cerebral cortex	UBERON:0000956	84.49	gold quality
frontal cortex	UBERON:0001870	84.40	gold quality
neocortex	UBERON:0001950	84.40	gold quality
Ammon’s horn	UBERON:0001954	83.91	gold quality
sural nerve	UBERON:0015488	83.55	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	83.30	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-11121	yes	428.11
E-MTAB-7316	yes	37.50
E-GEOD-137537	yes	17.51
E-HCAD-25	yes	7.61
E-MTAB-7381	no	49.99
E-ANND-3	no	5.99

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

308 targeting DOK6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-5696	99.98	72.36	4487

Literature-anchored findings (GeneRIF, showing 3)

• Dok-6 binds to the phosphorylated Ret Tyr(1062) residue resulting in phosphorylation of tyrosine residue(s) located within the unique C terminus of Dok-6 predominantly through a Src-dependent mechanism (PMID:15286081)
• DOK-6 is involved in RET signaling with less influence when compared with DOK-1, DOK-4, and SHC. (PMID:20210798)
• Association between ABHD1 and DOK6 polymorphisms and susceptibility to Hirschsprung disease in Southern Chinese children. (PMID:34545688)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	dok6	ENSDARG00000063032
mus_musculus	Dok6	ENSMUSG00000073514
rattus_norvegicus	Dok6	ENSRNOG00000038190
drosophila_melanogaster	Dok	FBGN0029944
drosophila_melanogaster	CG13398	FBGN0032042
caenorhabditis_elegans		WBGENE00018819

Paralogs (7): DOK5 (ENSG00000101134), DOK1 (ENSG00000115325), DOK4 (ENSG00000125170), FRS3 (ENSG00000137218), DOK3 (ENSG00000146094), DOK2 (ENSG00000147443), FRS2 (ENSG00000166225)

Protein

Protein identifiers

Docking protein 6 — Q6PKX4 (reviewed: Q6PKX4)

Alternative names: Downstream of tyrosine kinase 6

All UniProt accessions (2): Q6PKX4, J3KTH4

UniProt curated annotations — full annotation on UniProt →

Function. DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK6 promotes Ret-mediated neurite growth. May have a role in brain development and/or maintenance.

Subunit / interactions. Interacts via its PTB domain with phosphorylated RET.

Tissue specificity. Highly expressed in fetal and adult brain. Highly expressed in the cerebellum. Weak expression in kidney, spinal cord and testis.

Post-translational modifications. On Ret activation, phosphorylated on one or more C-terminal tyrosine residues by an Src family kinase.

Domain organisation. PTB domain mediates receptor interaction.

Similarity. Belongs to the DOK family. Type B subfamily.

RefSeq proteins (1): NP_689934* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001849	PH_domain	Domain
IPR002404	IRS_PTB	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR037816	DOK4/5/6_PH	Domain
IPR050996	Docking_Protein_DOK	Family

Pfam: PF00169, PF02174

UniProt features (7 total): domain 2, chain 1, region of interest 1, short sequence motif 1, compositionally biased region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6PKX4-F1	74.63	0.45

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8853659	RET signaling

MSigDB gene sets: 99 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, BENPORATH_ES_WITH_H3K27ME3, TGCGCANK_UNKNOWN, MARTIN_VIRAL_GPCR_SIGNALING_UP, ATTCTTT_MIR186, chr18q22, CAMPS_COLON_CANCER_COPY_NUMBER_UP, GOMF_SIGNALING_ADAPTOR_ACTIVITY, MIKKELSEN_MCV6_HCP_WITH_H3K27ME3, FIGUEROA_AML_METHYLATION_CLUSTER_1_UP, REACTOME_RET_SIGNALING, NRF1_Q6, REACTOME_NERVOUS_SYSTEM_DEVELOPMENT, HMG20B_TARGET_GENES, SOX3_TARGET_GENES

GO Biological Process (1): cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Axon guidance	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
enzyme-linked receptor protein signaling pathway	1
binding	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

730 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DOK6	GDNF	P39905	557
DOK6	CCDC102B	Q68D86	545
DOK6	RET	P07949	515
DOK6	RTTN	Q86VV8	512
DOK6	PLEK2	Q9NYT0	498
DOK6	PLEK	P08567	474
DOK6	EFR3A	Q14156	462
DOK6	DOK7	Q18PE1	460
DOK6	COL5A2	P05997	431
DOK6	SEMA3E	O15041	396
DOK6	CCDC61	Q9Y6R9	388
DOK6	STUM	Q69YW2	377
DOK6	QTGAL	Q67FW5	370
DOK6	H3BTC1	H3BTC1	370
DOK6	IRS4	O14654	369

IntAct

58 interactions, top by confidence:

A	B	Type	Score
C1orf94	DOK6	psi-mi:“MI:0915”(physical association)	0.560
RBPMS	DOK6	psi-mi:“MI:0915”(physical association)	0.560
DOK6	C1orf94	psi-mi:“MI:0915”(physical association)	0.560
DOK6	RBPMS	psi-mi:“MI:0915”(physical association)	0.560
DOK6	USP54	psi-mi:“MI:0915”(physical association)	0.560
LASP1	DOK6	psi-mi:“MI:0915”(physical association)	0.560
DOK6	FAM86C1P	psi-mi:“MI:0915”(physical association)	0.560
DOK6	METTL27	psi-mi:“MI:0915”(physical association)	0.560
ARID5A	DOK6	psi-mi:“MI:0915”(physical association)	0.560
CRYBB3	DOK6	psi-mi:“MI:0915”(physical association)	0.560
	DOK6	psi-mi:“MI:0915”(physical association)	0.560
DOK6	TBX15	psi-mi:“MI:0915”(physical association)	0.560
SLC30A6	DOK6	psi-mi:“MI:0915”(physical association)	0.560
DOK6	LGALS14	psi-mi:“MI:0915”(physical association)	0.560
DOK6	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
DOK6	ABHD11	psi-mi:“MI:0915”(physical association)	0.560
TLE5	DOK6	psi-mi:“MI:0915”(physical association)	0.560
DOK6	NTRK3	psi-mi:“MI:0915”(physical association)	0.550
DOK6	NTF3	psi-mi:“MI:0914”(association)	0.460
ESR2	FBLL1	psi-mi:“MI:0914”(association)	0.460
DOK6	EGFR	psi-mi:“MI:0407”(direct interaction)	0.440
DOK6	ERBB2	psi-mi:“MI:0407”(direct interaction)	0.440
DOK6	CNN1	psi-mi:“MI:0915”(physical association)	0.400
M		psi-mi:“MI:0914”(association)	0.350
DOK6	USP54	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (25): DOK6 (Two-hybrid), DOK6 (Two-hybrid), RET (Affinity Capture-Western), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid), DOK6 (Two-hybrid)

ESM2 similar proteins: A2VEA3, A5PKA5, A7MB76, O70133, O89050, P09851, P17427, P18484, P20595, P20936, P49336, P50904, P79101, P97834, Q08211, Q12800, Q28141, Q2MHE5, Q2TBL9, Q32NS4, Q3MHJ2, Q3UHD6, Q5M887, Q5R4Q7, Q5R874, Q5RB35, Q5RBN9, Q5RCG0, Q6GR10, Q6P5H6, Q6PKX4, Q7SXR3, Q7T2U9, Q7Z6J6, Q86TJ2, Q8K4V4, Q8N653, Q8R3L8, Q8R3S6, Q96DM3

Diamond homologs: A3R064, A7MBB8, B2RYG7, O43559, O60496, O70469, P97465, Q2MHE5, Q4QQV2, Q52RG8, Q5EA84, Q5RA30, Q6PKX4, Q7L591, Q8C180, Q8TEW6, Q8WU20, Q91WJ0, Q91ZM9, Q99704, Q99KE3, Q9P104, Q9QZK7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
RET	up-regulates	DOK6	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	38
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1526633	GRCh37/hg19 18q22.1-23(chr18:64340599-77273893)	Pathogenic

SpliceAI

4032 predictions. Top by Δscore:

Variant	Effect	Δscore
18:69401278:GGC:G	donor_gain	1.0000
18:69401301:G:GT	donor_gain	1.0000
18:69401307:TGGGG:T	donor_loss	1.0000
18:69401308:GGG:G	donor_gain	1.0000
18:69401309:GG:G	donor_gain	1.0000
18:69401309:GGG:G	donor_gain	1.0000
18:69401310:GG:G	donor_gain	1.0000
18:69401311:G:GG	donor_gain	1.0000
18:69401312:T:A	donor_loss	1.0000
18:69564485:A:AG	acceptor_gain	1.0000
18:69564486:G:GA	acceptor_gain	1.0000
18:69564486:G:GC	acceptor_loss	1.0000
18:69564486:GAT:G	acceptor_gain	1.0000
18:69564592:AAGGT:A	donor_loss	1.0000
18:69564595:G:T	donor_loss	1.0000
18:69564596:T:A	donor_loss	1.0000
18:69599378:TTCAA:T	acceptor_loss	1.0000
18:69599379:TCAA:T	acceptor_loss	1.0000
18:69599380:CAA:C	acceptor_loss	1.0000
18:69599381:A:AG	acceptor_gain	1.0000
18:69599381:AAG:A	acceptor_gain	1.0000
18:69599382:A:AT	acceptor_loss	1.0000
18:69599382:A:G	acceptor_gain	1.0000
18:69599383:G:GG	acceptor_gain	1.0000
18:69599383:G:GT	acceptor_loss	1.0000
18:69599494:GTCAG:G	donor_gain	1.0000
18:69599495:TCAG:T	donor_loss	1.0000
18:69599496:CAG:C	donor_loss	1.0000
18:69599497:AGGTA:A	donor_loss	1.0000
18:69599498:GGT:G	donor_loss	1.0000

AlphaMissense

2195 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:69401278:G:C	G12R	1.000
18:69401278:G:T	G12C	1.000
18:69401279:G:A	G12D	1.000
18:69401279:G:T	G12V	1.000
18:69401285:T:A	V14E	1.000
18:69564502:T:A	W28R	1.000
18:69564502:T:C	W28R	1.000
18:69564503:G:C	W28S	1.000
18:69564504:G:C	W28C	1.000
18:69564504:G:T	W28C	1.000
18:69564509:T:A	V30D	1.000
18:69564516:G:C	K32N	1.000
18:69564516:G:T	K32N	1.000
18:69564532:G:A	G38R	1.000
18:69564532:G:C	G38R	1.000
18:69564533:G:A	G38E	1.000
18:69564542:G:C	R41T	1.000
18:69564542:G:T	R41M	1.000
18:69564543:G:C	R41S	1.000
18:69564543:G:T	R41S	1.000
18:69564545:T:C	L42S	1.000
18:69564553:T:C	F45L	1.000
18:69564555:T:A	F45L	1.000
18:69564555:T:G	F45L	1.000
18:69564572:C:A	A51D	1.000
18:69599412:T:A	I68K	1.000
18:69599484:T:C	F92S	1.000
18:69599489:T:C	C94R	1.000
18:69599490:G:A	C94Y	1.000
18:69599491:T:G	C94W	1.000

dbSNP variants (sampled 300 via entrez): RS1000000181 (18:69684720 A>G), RS1000003496 (18:69421599 G>C), RS1000004317 (18:69417253 C>G,T), RS1000005556 (18:69691097 A>C), RS1000011133 (18:69541676 C>A), RS1000018623 (18:69546315 T>A,C), RS1000019574 (18:69703141 T>C), RS1000021533 (18:69835395 G>A), RS1000031026 (18:69464590 A>G), RS1000033864 (18:69793170 A>G), RS1000038887 (18:69716388 A>G), RS1000039437 (18:69542560 C>G,T), RS1000044619 (18:69458182 C>G), RS1000051168 (18:69546551 A>G), RS1000054808 (18:69582767 A>G)

Disease associations

OMIM: gene MIM:611402 | disease phenotypes: MIM:189800

GenCC curated gene-disease

Mondo (1): preeclampsia (MONDO:0005081)

Orphanet (1): Preeclampsia (Orphanet:275555)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000698_7	Osteoporosis-related phenotypes	9.000000e-07
GCST002343_9	Response to cytidine analogues (gemcitabine)	1.000000e-06
GCST004403_8	Bone fracture in osteoporosis	8.000000e-06
GCST004574_14	Skin aging (microtopography measurement)	1.000000e-06
GCST004970_28	Caudate activity during reward	6.000000e-08
GCST005024_25	Pursuit maintenance gain	8.000000e-06
GCST008167_5	Mean platelet volume	3.000000e-11
GCST010170_5	Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect)	3.000000e-06
GCST90002401_565	Platelet distribution width	2.000000e-13

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0008387	caudate nucleus measurement
EFO:0008396	response to reward
EFO:0008433	pursuit maintenance gain measurement
EFO:0005939	parental genotype effect measurement
EFO:0007984	platelet component distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, decreases methylation, increases methylation	5
Aflatoxin B1	decreases expression, decreases methylation, affects response to substance	4
bisphenol S	increases expression, affects cotreatment, decreases methylation	2
Vorinostat	affects cotreatment, increases expression, decreases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Valproic Acid	affects expression, decreases methylation	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, affects methylation	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
incobotulinumtoxinA	increases expression	1
Irinotecan	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, affects methylation, decreases methylation	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Cadmium	increases abundance, increases expression	1
Copper	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Lead	affects expression	1
Methotrexate	increases expression	1
Phthalic Acids	increases methylation	1
Quercetin	decreases expression	1
Silicon Dioxide	decreases expression	1
Testosterone	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial